3% Sodium Tetradecyl Sulfate Sclerotherapy Injections Impact on the Management of Hereditary Hemorrhagic Telangiectasia.

Overview

About this study

The purpose of this study is to explore the impact of sclerotherapy with intranasal intralesional injections with 3% sodium tetradecyl sulfate sclerotherapy (STS)  in subjects diagnosed with hereditary hemorrhagic telangiectasia (HHT).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:  

  • Age 18 years or more, and at least one sclerotherapy with intranasal, intralesional injection with 3% STS between January 2013 and August 2023 from Mayo Clinic Arizona.

Exclusion Criteria: 

  • Septodermoplasty, Young’s procedure, or laser photocoagulation after sclerotherapy with 3% STS.
  • Subjects treated with intranasal bevacizumab after sclerotherapy with 3% STS.
  • Patients within 3 months of their first treatment with sclerotherapy with 3% STS.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/20/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Devyani Lal, M.D.

Open for enrollment

Contact information:

Devyani Lal M.D.

Lal.Devyani@mayo.edu

More information

Publications

Publications are currently not available